FDA gives emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatment

The Food and Drug Administration on Monday issued an emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatment. The drug, praised by President Trump, was proven effective in clinical trials at reducing the need for hospitalizations in coronavirus patients at high risk of disease progression, the FDA said. Called bamlanivimab, it can be used in… Continue reading at New York Post